Identification of anthranilic acid derivatives as a novel class of allosteric inhibitors of hepatitis C NS5B polymerase

Journal of Medicinal Chemistry

Volumn 50, Issue 9, 2007, Pages 2108-2116

  Nittoli, Thomas ^a   Curran, Kevin ^a   Insaf, Shabana ^a   DiGrandi, Martin ^a   Orlowski, Mark ^a   Chopra, Rajiv ^a   Agarwal, Atul ^a   Howe, Anita Y M ^a   Prashad, Amar ^a   Floyd, M Brawner ^a   Johnson, Bernard ^a   Sutherland, Alan ^a   Wheless, Karen ^a   Feld, Boris ^a   O'Connell, John ^a   Mansour, Tarek S ^a   Bloom, Jonathan ^a  

^a WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [2 (4 CHLORPHENOXY)ACETYLAMINO]BENZOIC ACID; ANTHRANILIC ACID DERIVATIVE; ANTIVIRUS AGENT; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED RNA POLYMERASE; RNA DIRECTED RNA POLYMERASE INHIBITOR; RNA DIRECTED RNA POLYMERASE NS5B; RNA POLYMERASE II; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SELECTIVITY; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IC 50; INHIBITION KINETICS; NONHUMAN; REPLICON; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION; X RAY CRYSTALLOGRAPHY;

ALLOSTERIC REGULATION; ANTHRANILIC ACIDS; ANTIVIRAL AGENTS; BINDING SITES; CELL LINE; CRYSTALLOGRAPHY, X-RAY; HEPACIVIRUS; HUMANS; MODELS, MOLECULAR; REPLICON; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 34247573851     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm061428x     Document Type: Article

References (34)

1. Matsuura, Y. Expression and characterization of hepatitis C virus (HCV) proteins. Uirushu 1995, 45, 105-115.
2. Farci, P.; Alter, J. H.; Shimoda, A.; Govindarajan, S.; Cheung, L. C.; Melpolder, J. C.; Sacher, R. A.; Shih, J. W.; Purcell, R. H. Hepatitis C virus-associated fulminant hepatic failure. N. Engl. J. Med. 1996, 335, 631-634.
3. Hoofnagle, J. H. Hepatitis C-the clinical spectrum of disease. Hepatology 1997, 26, S15-S20.
4. McHutchison, J. G. Understanding hepatitis C. Am. J. Manag. Care 2004, 10, S21-29.
5. National Institutes of Health Consensus Development Conference Panel. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 1997, 26(suppl 1), 2S-10S.
6. Alter, M. J.; Kruszon-Moran, D.; Nainan, O. V.; McQuillan, G. M.; Gao, F.; Moyer, L. A.; Kaslow, R. A.; Margolis, H. S. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N. Engl. J. Med. 1999, 341, 556-562.
7. Tan, S.; Pause, A.; Shi, Y.; Sonenberg, N. Hepatitis C therapeutics: Current status and emerging strategies. Nat. Rev. Drug Discovery 2002, 11, 867-881.
8. McHutchison, J. G.; Gordon, S. C; Schiff, E.R.; Shiffman, M. L.; Lee, W. M.; Rustgi, V. K.; Goodman, Z. D.; Ling, M.; Cort, S.; Albrecht, J. K. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 1998, 339, 1485-1492.
9. Manns, M. P.; McHutchison, J. G.; Gordon, S. C.; Rustgi, V. K.; Shiffman, M.; Reindollar, R.; Goodman, Z. D.; Koury, K.; Ling, M.; Albrecht, J. K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358, 958-965.
10. Asahina, Y.; Izumi, N.; Enomoto, N.; Kurosaki, M.; Onuki, Y.; Nishimura, Y.; Ueda, K.; Tsuchiya, K.; Nakanishi, H.; Kitamura, T.; Miyake, S. Mutagenic effects of ribavirin and response to interferon/ ribavirin combination therapy in chronic hepatitis C. J. Hepatol. 2005, 43, 623-629.
11. Dixit, N. M.; Perelson. The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus. Cell Mol. Life Sci. 2006, 63, 832-842.
12. (a) Pawlotsky, J.; McHutchison, J. G. Hepatitis C. Development of new drugs and clinical trials: promises and pitfalls. Summary of an AASLD Hepatitis Single Topic Conference, Chicago, IL, February 27-March 1, 2003.
13. (b) Nakagawa, S.; Umehara, T.; Matsuda, C.; Kuge, S.; Sudoh, M.; Kohara, M. Hsp90 inhibitors suppress HCV replication in replicon cells and humanized liver mice. Biochem. Biophys. Res. Commun. 2007, 353, 882-888.
14. McHutchison, J. G.; Manns, M.; Keyur, P.; Poynard, T.; Lindsay, K. L.; Trepo, C.; Dienstag, J.; Lee, W. M.; Mak, C.; Garaud, J.; Albrect, J. K. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002, 123, 1061-1069.
15. (a) Gordon, C. P.; Keller, P. A. Control of hepatitis C: A medicinal chemistry perspective. J. Med. Chem. 2005, 48, 1-20.
16. (b) De Francesco, R.; Migliaccio, G. Challenges and successes in developing new therapies for hepatitis C. Nature 2005, 436, 953-960.
17. (a) Carroll, S. S.; Olsen, D. B. Nucleoside analog inhibitors of hepatitis C virus replication. Infectious Disorders: Drug Targets 2006, 6, 17-29.
18. (b) Yan, S.; Appleby, T.; Gunic, E.; Shim, J. H.; Tasu, T.; Kim, H.; Rong, F.; Chen, H.; Hamatake, R.; Wu, J. Z.; Hong, Z.; Yao, N. Isothiazoles as active-site inhibitors of HCV NS5B polymerase. Bioorg. Med. Chem. Lett. 2007, 17, 28-33.
19. (a) Koch, U.; Narjes, F. Allosteric inhibition of the hepatitis C virus NS5B RNA dependent RNA polymerase. Infect. Disord.: Drug Targets 2006, 6, 31-41.
20. (b) Beaulieu, P. L. The discovery of finger loop inhibitors of the hepatitis C virus NS5B polymerase: status and prospects for novel HCV therapeutics. IDrugs 2006, 9, 39-43.
21. (a) Gopalsamy, A.; Shi, M.; Ciszewski, G.; Park, K.; Ellingboe, J. W.; Orlowski, M.; Feld, B.; Howe, A. Y. M. Design and synthesis of 2,3,4,9-tetrahydro-1H-carbazole and 1,2,3,4-tetrahydro-cyclopenta[b]indole derivatives as non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA polymerase. Bioorg. Med. Chem. Lett. 2006, 16, 2532-2534.
22. (b) Gopalsamy, A; Aplasca, A.; Ciszewski, G.; Park, K.; Ellingboe, J. W.; Orlowski, M.; Feld, B; Howe, A. Y. M. Design and synthesis of 3,4-dihydro-1H-[1]-benzothieno[2,3-c]-pyran and 3,4-dihydro-1H-pyrano[3,4-b] benzofuran derivatives as non-nucleoside inhibitors of HCV NS5B RNA dependent RNA polymerase. Bioorg. Med. Chem. Lett. 2006, 16, 457-460.
23. (c) Gopalsamy, A.; Lim, K.; Ciszewski, G.; Park, K.; Ellingboe, J. W.; Bloom, J.; Insaf, S.; Upeslacis, J.; Mansour, T. S.; Krishnamurthy, G.; Damarla, M.; Pyatski, Y.; Ho, D.; Howe, A. Y. M.; Orlowski, M.; Feld, B.; O'Connell, J. Discovery of Pyrano[3,4-b]indoles as Potent and Selective HCV NS5B Polymerase Inhibitors. J. Med. Chem. 2004, 47, 6603-6608.
24. (d) Gopalsamy, A.; Lim, K.; Ellingboe, J. W.; Krishnamurthy, G.; Orlowski, M.; Feld, B.; van Zeijl, M.; Howe, A. Y. M. Identification of [(naphthalene-1-carbonyl)-amino]-acetic acid derivatives as nonnucleoside inhibitors of HCV NS5B RNA dependent RNA polymerase. Bioorg. Med. Chem. Lett. 2004, 14, 4221-4224.
25. Gopalsamy, A.; Chopra, R.; Lim, K.; Ciszewski, G.; Shi, M.; Curran, K. J.; Sukits, S. F.; Svenson, K.; Bard, J.; Ellingboe, J. W.; Agarwal, A.; Krishnamurthy, G.; Howe, A. Y. M.; Orlowski, M.; Feld, B.; O'Connell, J.; Mansour, T. S. Discovery of proline sulfonamides as potent and selective hepatitis C virus NS5b polymerase inhibitors, evidence for a new NS5b polymerase binding site. J. Med. Chem. 2006, 49, 3052-3055.
26. (a) Powers, J. P.; Piper, D. E.; Li, Y.; Mayorga, V.; Anzola, J.; Chen, J. M.; Jaen, J. C.; Lee, G.; Liu, J.; Peterson, M. G.; Tonn, G. R.; Ye, Q.; Walker, N. P. C.; Wang, Z. SAR and mode of action of novel non-nucleoside inhibitors of hepatitis C NS5b RNA polymerase. J. Med. Chem. 2006, 49, 1034-1046.
27. (b) Pfefferkorn, J. A.; Greene, M. L.; Nugent, R. A.; Gross, R. J.; Mitchell, M. A.; Finzel, B. C.; Harris, M. S.; Wells, P. A.; Shelly, J. A.; Anstadt, R. A.; Kilkuskie, R. E.; Kopta, L. A.; Schwende, F. J. Inhibitors of HCV NS5B polymerase. Part 1: Evaluation of the southern region of (2Z)-2-(benzoylamino)-3-(5-phenyl-2-furyl)acrylic acid. Bioorg. Med. Chem. Lett. 2005, 15, 2481-2486.
28. (c) Pfefferkorn, J. A.; Nugent, R.; Gross, R. J.; Greene, M.; Mitchell, M. A.; Reding, M. T.; Funk, L. A.; Anderson, R.; Wells, P. A.; Shelly, J. A.; Anstadt, R.; Finzel, B. C.; Harris, M. S.; Kilkuskie, R. E.; Kopta, L. A.; Schwende, F. J. Inhibitors of HCV NS5B polymerase. Part 2: Evaluation of the northern region of (2Z)-2-benzoylamino-3-(4-phenoxy-phenyl)-acrylic acid. Bioorg. Med. Chem. Lett. 2005, 15, 2812-2818.
29. Sugasawa, T.; Toyoda, T.; Adachi, M.; Sasakura, K. Aminohaloborane in organic synthesis. 1. Specific ortho substitution reaction of anilines. J. Am. Chem. Soc. 1978, 100, 4842-4852.
30. Rao, A. V. R.; Gaitonde, A. S.; Prakash, K. R. C.; Rao, S. P. A concise synthesis of chiral 2-methyl chroman-4-ones: Stereo selective build-up of the chromanol moiety of anti-HIV agent, calanolide A. Tetrahedron Lett. 1994, 35, 6347-6350.
31. Howe, A. Y.; Bloom, J.; Baldick, C.; Christophers, J.; Cheng, H.-M.; Christensen, J. S.; Chunduru, S. K.; Coburn, G. A.; Feld, B.; Gopalsamy, A.; Gorczyca, W. P.; Herrman, S.; Johann, S.; Jiang, X.; Kimberland, M. L.; Krishnamurthy, G.; Olson, M. W.; Orlowski, M.; Swanberg, S.; Thompson, I.; Thorn, M.; Del Vecchio, A. M.; Young, D. C.; van Zeijl, M.; Ellingboe, J. W.; Upeslacis, J.; Collett, M. S.; Mansour, T. S.; O'Connell, J. Indentification of a novel non-nucleoside inhibitor of hepatitis C virus RNA-dependent RNA polymerase. Antimicrob. Agents Chemother. 2004, 48, 4813-4821.
32. Liu, C.; Chopra, R.; Swanberg, S.; Olland, S.; O'Connell, J.; Herrmann, S. Elongation of synthetic RNA templates by hepatitis C virus NS5B polymerase. J. Biol. Chem. 2004, 279, 10738-10746.
33. CCP4. 1994. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D50, 760-763.
34. Lesburg, Charles A.; Cable, Michael B.; Ferrari, Eric; Hong, Zhi; Mannarino, Anthony F.; Weber, Patricia C. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat. Struct. Biol. 1999, 6, 937-943.